Literature DB >> 19027307

A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours.

E B de Araújo1, J S Caldeira Filho, L T Nagamati, E Muramoto, M T Colturato, R M Couto, P B Pujatti, J Mengatti, C P G Silva.   

Abstract

This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to (177)Lu-DOTATATE and with lower abdominal uptake than (131)I-TATE. In addition, (131)I-DOTATATE showed significative tumour uptake, despite not so persistent after 24h. (131)I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19027307     DOI： 10.1016/j.apradiso.2008.09.009

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  5 in total

Review 1.  Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature.

Authors:  Mutlu Dogan; Bulent Yalcin; Nuriye Yildirim Ozdemir; Ulku Yalcintas Arslan; Lutfi Dogan; Gungor Utkan; Hakan Akbulut; Nurullah Zengin; Necati Alkis; Fikri Icli
Journal:  Med Oncol       Date:  2011-05-27       Impact factor: 3.064

2.  Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

Authors:  Aurora Sainz-Esteban; Vikas Prasad; Christiane Schuchardt; Carolin Zachert; José Manuel Carril; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

3.  Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells.

Authors:  Hossein Behnammanesh; Mostafa Erfani; Maliheh Hajiramezanali; Safura Jokar; Parham Geramifar; Omid Sabzevari; Mohsen Amini; Seyed Mohammad Mazidi; Davood Beiki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

4.  The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts.

Authors:  Sara Lundsten; Diana Spiegelberg; Nakul R Raval; Marika Nestor
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-07       Impact factor: 9.236

Review 5.  Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC.

Authors:  Nasim Vahidfar; Saeed Farzanehfar; Mehrshad Abbasi; Siroos Mirzaei; Ebrahim S Delpassand; Farzad Abbaspour; Yalda Salehi; Hans Jürgen Biersack; Hojjat Ahmadzadehfar
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.